spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  dalbavancin 

 HSMN NewsFeed - 16 Mar 2020
ADVANZ PHARMA Corp. Limited to Acquire Specialty Pharmaceutical Company Correvio Pharma Corp.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Mar 2020
ADVANZ PHARMA to Acquire Correvio
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Dec 2019
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 11 Dec 2019
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 11 Nov 2019
Allergan Receives FDA Qualified Infectious Disease Product (QIDP) Designation And Fast Track Designation For ATM-AVI (Aztreonam And Avibactam) For Antibiotic-Resistant Gram-Negative Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Jul 2019
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 24 Jun 2019
Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 2 Jan 2019
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 May 2018
Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess(R) in China
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 17 Apr 2018
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 12 Dec 2017
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 12 Sep 2017
Cardiome Announces Agreement with Basilea for Distribution of Zevtera(R)/Mabelio(R) (Ceftobiprole) in Europe and Israel
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 21 Aug 2017
Cardiome Provides U.S. Regulatory Update For BRINAVESS
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 21 Jun 2017
Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Jun 2017
Cardiome Announces Commercial Launch of BRINAVESS(R) (Vernakalant Hydrochloride) in Canada
Biopharmaceuticals Cardiology Product Launch
 HSMN NewsFeed - 3 Mar 2017
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 8 Dec 2016
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 29 Nov 2016
Cardiome Advances Toward the UK XYDALBA(TM) (dalbavancin) Launch
Biopharmaceuticals Reimbursement Product Launch
 HSMN NewsFeed - 12 May 2016
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
Biopharmaceuticals Cardiology Product Launch
 HSMN NewsFeed - 21 Jan 2016
Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE(R) (dalbavancin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Jul 2014
Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 26 Jul 2012
Durata Therapeutics Adds Independent Director Lisa M. Giles to the Company’s Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2012
Durata Therapeutics Appoints John P. Shannon as Chief Commercial Officer with Responsibility to Build Commercial Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Apr 2011
Durata Therapeutics Initiates Phase 3 Study of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Biopharmaceuticals
 HSMN NewsFeed - 21 Dec 2009
Newly Formed Durata Therapeutics Acquires Pfizer's Vicuron Subsidiary
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 9 Sep 2008
Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial
Biopharmaceuticals Regulatory FDA
 HSMN NewsFeed - 21 Dec 2007
Pfizer Receives Approvable Letter from FDA for Dalbavancin
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 23

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 23 additional stories matching:
dalbavancin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.